Page 7 - Aduhelm News Today

WASHINGTON (AP) — A stronger-than-expected economic recovery from the pandemic has...

Biden has also endorsed a plan to funnel more money to private insurance companies and escalating plans to privatize the government program for seniors that insures 63 million.

WASHINGTON (AP) — A stronger-than-expected economic recovery from the pandemic has...

WASHINGTON (AP) — Medicare recipients will get a premium reduction — but not until...

Medicare's decision to limit coverage for a controversial new Alzheimer's drug has prompted an outcry among Alzheimer's advocates. The drug is Aduhelm, and despite widespread enthusiasm for it among Alzheimer's patients and advocates, it hasn't been proven to slow the disease. The drug was given accelerated approval by the Food and Drug Administration because it reduces the plaque that develops in the brains of most Alzheimer’s patients.

Biogen Inc said on Tuesday that Chief Executive Michel Vounatsos will step down and that the company is ...

Biogen Inc said on Tuesday that Chief Executive Michel Vounatsos will step down and that the company is pulling back on selling its Alzheimers drug Aduhelm after the U.S. governments Medicare... | May 3, 2022

The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefits and serious safety risks.

Biogen will replace its CEO and largely abandon marketing of its controversial...

Biogen’s aducanumab, already hamstrung in the U.S. by a stifling coverage decision, won’t be hitting the European market anytime soon.